The IFI27 Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human pancreatic cancer line PaTu 8988t, engineered for loss-of-function studies of the IFI27 gene. This product is supplied as a heterogeneous population of cells harboring targeted disruption of IFI27, generated via non-viral CRISPR/Cas9 delivery, without single-cell cloning or biallelic knockout selection. The polyclonal format preserves the functional diversity of gene-edited cells, enabling robust analysis of IFI27-dependent phenotypes in a complex cellular context. Researchers can utilize this model to interrogate the gene??s role in interferon signaling, apoptosis, and cell cycle control, leveraging the pooled genetic variance to assess pathway perturbations at the population level.
The parental PaTu 8988t cell line is a well-characterized human pancreatic ductal adenocarcinoma (PDAC) model established from a liver metastasis. These cells are epithelial in origin and carry an activating KRAS G12V mutation, a hallmark driver of PDAC aggressiveness and therapeutic resistance. PaTu 8988t exhibits intrinsic metastatic potential, making it a physiologically relevant platform for studying advanced pancreatic cancer biology. The cells grow as adherent monolayers and maintain genomic instability typical of PDAC, providing a faithful tumor microenvironment-independent system for mechanistic and pharmacological investigations.
IFI27 encodes an interferon-inducible protein that acts as a critical node in type I interferon responses. Transcriptionally activated by the ISGF3 complex (comprising STAT1, STAT2, and IRF9) downstream of IFNAR1/2 engagement and JAK1/TYK2 kinases, IFI27 is also regulated by IRF1, IRF3, and IRF7. Its molecular function centers on promoting mitochondrial-mediated apoptosis and cell cycle arrest. Mechanistically, IFI27 interacts with BCL2L1 (Bcl-xL) and BAX at the mitochondrial outer membrane, facilitating cytochrome c release and caspase activation. Additionally, IFI27 associates with NDUFA13 (GRIM-19), a subunit of complex I, and modulates cell cycle inhibitors such as p21, linking interferon signaling to proliferative arrest.
Disruption of IFI27 in the PaTu 8988t background ablates interferon-induced apoptotic execution and growth suppression, thereby enhancing tumor cell survival and clonogenic expansion. This knockout model captures the loss of a key tumor-suppressive arm of the IFN signaling axis, mirroring immune evasion mechanisms observed in pancreatic cancer. Given the KRAS-driven oncogenic context, IFI27 loss cooperates with intrinsic proliferative signals, potentially accelerating metastatic progression. Consequently, this system is ideally suited for dissecting how interferon signaling interfaces with mitochondrial death pathways and for evaluating strategies to restore apoptosis sensitivity in PDAC.
Applications of the IFI27 Knockout PaTu 8988t Polyclonal Cells span interferon biology, apoptosis research, and pancreatic cancer drug discovery. They enable detailed dose?Cresponse studies with type I interferons, comparative analysis of IFN-stimulated gene expression via RT-qPCR, and assessment of mitochondrial apoptotic effectors through Western blotting for Bcl-xL, BAX, and cleaved caspases. Functional assays such as MTT, Annexin V/PI flow cytometry, caspase-3/7 activity measurement, colony formation, and Transwell migration/invasion can be employed to quantify apoptotic, proliferative, and invasive phenotypes. These cells are also valuable for screening small molecules that modulate interferon sensitivity or overcome apoptotic resistance, and for modeling immunotherapy responses in co-culture settings. For technical guidance or to discuss custom applications, please contact Ascent Research.
